Abstract
Anti-idiotype (Id) vaccine therapy has been tested and shown to be effective, in several animal models, for triggering the immune system to induce specific and protective immunity against bacterial, viral and parasitic infections. The administration of anti-Id antibodies as surrogate tumor-associated antigens (TAA) also represents another potential application of the concept of the Id network. Limited experience in human trials using anti-Id to stimulate immunity against tumors has shown promising results. In this “counterpoint” article, we discuss our own findings showing the potential of anti-Id antibody vaccines to be novel therapeutic approaches to various human cancers and also discuss where anti-Id vaccines may perform better than traditional multiple-epitope antigen vaccines.
Article PDF
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 27 December 1999 / Accepted: 27 January 2000
Rights and permissions
About this article
Cite this article
Bhattachary-Chatterjee, M., Nath Baral, R., Chatterjee, S. et al. Counterpoint. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine. Cancer Immunol Immunother 49, 133–141 (2000). https://doi.org/10.1007/s002620050612
Issue Date:
DOI: https://doi.org/10.1007/s002620050612